Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0184 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.6599 |
| Open | 1.6158 |
| 1-Year Change | 127.58% |
| Day's Range | 1.5358 - 1.6158 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 9, 2024 | 1.6599 | -0.0300 | -1.78% | 1.6899 | 1.7099 | 1.6099 |
| May 8, 2024 | 1.7099 | 0.1800 | 11.77% | 1.5299 | 1.7399 | 1.5099 |
| May 7, 2024 | 1.5599 | -0.0500 | -3.11% | 1.6099 | 1.6999 | 1.5099 |
| May 6, 2024 | 1.6299 | 0.2900 | 21.64% | 1.3399 | 1.6399 | 1.3399 |
| May 3, 2024 | 1.3199 | -0.0500 | -3.65% | 1.3699 | 1.4099 | 1.3199 |
| May 2, 2024 | 1.3299 | -0.0600 | -4.32% | 1.3899 | 1.3999 | 1.3199 |
| May 1, 2024 | 1.3799 | 0.0700 | 5.34% | 1.3099 | 1.4299 | 1.3099 |
| Apr 30, 2024 | 1.3099 | -0.0600 | -4.38% | 1.3699 | 1.3799 | 1.2499 |
| Apr 29, 2024 | 1.3799 | 0.1200 | 9.52% | 1.2599 | 1.4299 | 1.2599 |
| Apr 26, 2024 | 1.2699 | 0.0700 | 5.83% | 1.1999 | 1.2999 | 1.1899 |
| Apr 25, 2024 | 1.1699 | 0.0200 | 1.74% | 1.1499 | 1.2399 | 1.1099 |
| Apr 24, 2024 | 1.1699 | -0.1100 | -8.59% | 1.2799 | 1.2799 | 1.1499 |
| Apr 23, 2024 | 1.2299 | 0.0200 | 1.65% | 1.2099 | 1.2999 | 1.1699 |
| Apr 22, 2024 | 1.2299 | -0.1200 | -8.89% | 1.3499 | 1.3499 | 1.1999 |
| Apr 19, 2024 | 1.3099 | 0.0300 | 2.34% | 1.2799 | 1.3599 | 1.2699 |
| Apr 18, 2024 | 1.3099 | -0.1600 | -10.89% | 1.4699 | 1.5199 | 1.2699 |
| Apr 17, 2024 | 1.4299 | -0.1600 | -10.06% | 1.5899 | 1.6299 | 1.3999 |
| Apr 16, 2024 | 1.5799 | 0.0500 | 3.27% | 1.5299 | 1.5899 | 1.5199 |
| Apr 15, 2024 | 1.5799 | -0.0800 | -4.82% | 1.6599 | 1.6799 | 1.5199 |
| Apr 12, 2024 | 1.6999 | 0.0300 | 1.80% | 1.6699 | 1.7499 | 1.5999 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com